Ann Dermatol.  2016 Feb;28(1):30-39. 10.5021/ad.2016.28.1.30.

Genetic Risk Factors for Psoriasis in Turkish Population: -1540 C/A, -1512 Ins18, and +405 C/G Polymorphisms within the Vascular Endothelial Growth Factor Gene

• Bozduman T
• Ersoy Evans S
• Karahan S
• Hayran Y
• Akbiyik F
• Lay I

• KMID: 2429479
• DOI: http://doi.org/10.5021/ad.2016.28.1.30

Abstract

BACKGROUND
Evidence regarding the vascular endothelial growth factor A (VEGFA) as a potent mediator of angiogenesis and inflammation in psoriasis has revealed variations in this gene as surrogate markers of psoriasis.
OBJECTIVE
VEGFA gene polymorphisms (-1540 C/A, -1512 Ins18, -460 T/C, and +405 C/G) in psoriasis susceptibility in Turkish population were investigated.
METHODS
A total of 200 age, sex and ethnicity-matched psoriatic and healthy individuals were examined for clinical type, response to therapy, serum VEGFA and its receptor levels, genotypes and haplotypes.
RESULTS
The +405 GG, +405 CG, -1540 CA, and -1512 +Ins18 genotypes conferred a significant risk for developing psoriasis. The C-InsTC haplotype in the controls and C+InsTG, A+InsTC, and A-InsTG haplotypes in psoriatic patients were observed to be significantly high. Increased serum levels of VEGFA were detected in psoriatic patients with the C-InsTC haplotype than that in the controls. The +405 GG genotype was significantly more frequent in psoriatic patients with a positive family history, and the moderate form of psoriasis was more frequent among C+InsTG haplotype carriers than that among the other patients. The +405 GG genotype was found to be more frequent in patients responding to oral retinoids. Serum VEGFR1/FLT1 and VEGFR2/KDR levels were not significantly different when psoriatic patients and controls were stratified based on the risk polymorphic variants.
CONCLUSION
VEGFA gene +405 GG and CG, -1512+Ins18, and -1540 CA genotypes are associated with an increased risk of psoriasis in Turkish population. The G allele at +405 and an 18-bp insertion at -1512 are primarily the risk factors for psoriasis, and this risk is potentiated by the presence of the A allele at the -1540 locus.

Keyword

Angiogenesis; Psoriasis; Turkish population; Vascular endothelial growth factor; VEGFA gene polymorphisms

MeSH Terms

Alleles
Biomarkers
Genotype
Haplotypes
Humans
Inflammation
Psoriasis*
Retinoids
Risk Factors*
Vascular Endothelial Growth Factor A*
Retinoids
Vascular Endothelial Growth Factor A

Reference

1. Elder JT. Psoriasis clinical registries, genetics, and genomics. Ann Rheum Dis. 2005; 64:Suppl 2. ii106–ii107.

2. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997; 6:813–820.

3. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005; 352:1899–1912.

4. Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D. Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol. 1998; 110:958–960.

5. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996; 93:1493–1495.

6. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009; 90:232–248.

7. Ribatti D. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol. 2005; 128:303–309.

8. Detmar M. Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J Invest Dermatol. 2004; 122:xiv–xxv.

9. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994; 180:1141–1146.

10. Man XY, Yang XH, Cai SQ, Bu ZY, Zheng M. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med. 2008; 12:649–660.

11. Zhang Y, Matsuo H, Morita E. Vascular endothelial growth factor 121 is the predominant isoform in psoriatic scales. Exp Dermatol. 2005; 14:758–764.

12. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999; 141:1054–1060.

13. Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol. 2002; 138:791–796.

14. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 2003; 102:161–168.

15. Bottomley MJ, Webb NJ, Watson CJ, Holt L, Bukhari M, Denton J, et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol. 2000; 119:182–188.

16. Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007; 25:524–528.

17. Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis. 2002; 5:231–236.

18. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983; 275:181–189.

19. Kneilling M, Hültner L, Pichler BJ, Mailhammer R, Morawietz L, Solomon S, et al. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum. 2007; 56:1806–1816.

20. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest. 2000; 80:1195–1205.

21. Watanabe H, Mamelak AJ, Wang B, Howell BG, Freed I, Esche C, et al. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Exp Dermatol. 2004; 13:671–681.

22. Ruggiero D, Dalmasso C, Nutile T, Sorice R, Dionisi L, Aversano M, et al. Genetics of VEGF serum variation in human isolated populations of cilento: importance of VEGF polymorphisms. PLoS One. 2011; 6:e16982.

23. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 1999; 60:1245–1249.

24. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000; 12:1232–1235.

25. Jiménez-Sousa MA, Fernández-Rodríguez A, Heredia M, Tamayo E, Guzmán-Fulgencio M, Lajo C, et al. Genetic polymorphisms located in TGFB1, AGTR1, and VEGFA genes are associated to chronic renal allograft dysfunction. Cytokine. 2012; 58:321–326.

26. Chen Y, Dawes PT, Mattey DL. Polymorphism in the vascular endothelial growth factor A (VEGFA) gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis: differential effect of cigarette smoking. Cytokine. 2012; 58:390–397.

27. Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications. 2003; 17:1–6.

28. Kamoun M, Houman MH, Hamzaoui A, Hamzaoui K. Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet's disease. Tissue Antigens. 2008; 72:581–587.

29. Breunis WB, Biezeveld MH, Geissler J, Ottenkamp J, Kuipers IM, Lam J, et al. Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum. 2006; 54:1588–1594.

30. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 2003; 34:383–394.

31. Boiardi L, Casali B, Nicoli D, Farnetti E, Chen Q, Macchioni P, et al. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. J Rheumatol. 2003; 30:2160–2164.

32. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003; 63:812–816.

33. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002; 51:1635–1639.

34. Barile S, Medda E, Nisticò L, Bordignon V, Cordiali-Fei P, Carducci M, et al. Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. Exp Dermatol. 2006; 15:368–376.

35. Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006; 126:453–459.

36. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol. 2004; 122:209–215.

37. Zablotna M, Sobjanek M, Nedoszytko B, Lange M, Kozicka D, Glen J, et al. Association of psoriasis with the VEGF gene polymorphism in the northern Polish population. J Eur Acad Dermatol Venereol. 2013; 27:319–323.

38. Wongpiyabovorn J, Yooyongsatit S, Ruchusatsawat K, Avihingsanon Y, Hirankarn N. Association of the CTG (-2578/-460/+405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis. Tissue Antigens. 2008; 72:458–463.

39. Wang Z, Liang W, Zhang B, Lv M, Wang J, Zhang L. Single nucleotide polymorphisms of VEGF gene and Psoriasis risk. J Dermatol Sci. 2008; 49:263–265.

40. Wu J, Ren X, Zhang X, Li C, Li Y, Ma H, et al. The vascular endothelial growth factor +405 G/C polymorphism in psoriasis. J Dermatol Sci. 2010; 57:62–63.

41. Lee JH, Cho EY, Namkung JH, Kim E, Kim S, Shin ES, et al. Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans. J Invest Dermatol. 2008; 128:1599–1603.

42. Butt C, Lim S, Greenwood C, Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord. 2007; 8:1.

43. Qi M, Huang X, Zhou L, Zhang J. Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis. DNA Cell Biol. 2014; 33:234–244.

44. Stefanaki I, Dimisianos G, Antoniou C, Katsambas A, Stratigos A. Investigation of +405 and -460 polymorphisms of vascular endothelial growth factor in psoriasis and short-term responsiveness to efalizumab therapy. Dermatology. 2008; 217:201–202.

45. Bowes J, Ho P, Flynn E, Salah S, McHugh N, FitzGerald O, et al. Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. Ann Rheum Dis. 2012; 71:313–314.

46. Carlström M, Ekman AK, Petersson S, Enerbäck C. Lack of evidence for association of VEGF polymorphisms in Swedish patients with psoriasis. J Invest Dermatol. 2012; 132:1510–1513.

47. Lip GY, Chung I. Vascular endothelial growth factor and angiogenesis in heart failure. J Card Fail. 2005; 11:285–287.

48. Lenny N, Westendorf JJ, Hiebert SW. Transcriptional regulation during myelopoiesis. Mol Biol Rep. 1997; 24:157–168.